Direxion Daily Semiconductor Bull 3X Shares vs Viatris Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $122.77, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and Viatris Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SOXL | VTRS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $17.86 |
52-Week Low | $28.60 | $9.49 |
Market Cap | — | $19.09B |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, gained 5.19% to $123.37, reflecting strong bullish momentum in semiconductor stocks. Technical indicators show a bullish overall signal with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights ongoing institutional interest in semiconductor ETFs despite warnings about potential short-term volatility and tariff concerns from US trade policy discussions.
The outlook for SOXL remains tied to semiconductor sector performance, with AI demand providing long-term support. However, investors face significant risks from volatility decay inherent in leveraged ETFs, potential tariff impacts, and crowded trading positioning that could trigger sharp corrections. The ETF's performance is highly correlated with major semiconductor stocks like NVIDIA.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Trailing returns across standard periods
Latest headlines on both assets
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →